|
Cohort1: Recurrent or Refractory Medulloblastoma/PNET Patients
|
| Administration route |
intravenous injection |
| Pts |
1 |
| Age |
Child, Adult |
| Adverse reactions |
1/1(Nervous system disorders) |
|
|
Cohort2: Recurrent or refractory high-grade glioma patients
|
| Administration route |
intravenous injection |
| Pts |
1 |
| Age |
Child, Adult |
| Adverse reactions |
No serious clinical adverse events |
|
|
Cohort3: Phase-II stratum for Recurrent or Refractory Medulloblastoma/PNET Patients
|
| Administration route |
intravenous injection |
| Pts |
8 |
| Age |
Child, Adult |
| Adverse reactions |
3/8(Metabolism and nutrition disorders; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders; Psychiatric disorders; Respiratory, thoracic and mediastinal disorders) |
|
|
Cohort4: Phase-II stratum for Recurrent or refractory high-grade glioma patients
|
| Administration route |
intravenous injection |
| Pts |
18 |
| Age |
Child, Adult |
| Adverse reactions |
4/18(General disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders) |
|
|
Cohort5: Phase-II stratum for Recurrent or refractory ependymoma patients
|
| Administration route |
intravenous injection |
| Pts |
4 |
| Age |
Child, Adult |
| Adverse reactions |
2/4(Gastrointestinal disorders; General disorders; Nervous system disorders) |
|
|
Cohort6: Phase-II stratum for Recurrent or refractory diffuse intrinsic pontine gliomas (DIPG) patients
|
| Administration route |
intravenous injection |
| Pts |
8 |
| Age |
Child, Adult |
| Adverse reactions |
3/8(General disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders; Respiratory, thoracic and mediastinal disorders) |
|